Vixarelimab
- Generic Name
- Vixarelimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2243320-83-2
- Unique Ingredient Identifier
- W25GO3A75W
- Background
Vixarelimab is under investigation in clinical trial NCT03816891 (A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Prurigo Nodularis).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT06137183
- Locations
- 🇺🇸
Henry Ford Health System, Novi, Michigan, United States
🇺🇸Mayo Clinic - PPDS, Rochester, Minnesota, United States
🇺🇸University of Utah - Health Sciences Center - PPDS, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath